Issue

Vol. 64 No. 9: Issue 9

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

The roles of DNA epigenetics and clinical significance in Chronic Myeloid Leukemia: a review

https://doi.org/10.14715/cmb/2018.64.9.9
Aliasghar Keramatinia
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Alireza Ahadi
Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Mohammad Esmaeil Akbari
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Maryam Mohseny
Department of Social Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Alireza Mosavi Jarahi
Department of Social Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Ayad Bahadori-Monfared
Department of Social Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Mehrdad Hashemi
Department of Molecular Genetics, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
Afshin Moradi
Department of Pathology, Shohada Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran
Narjes Mehrvar
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Elham Kazemi
Department of Sexual Medicine, The Rhazes Center for Research in Family Health and Sexual Medicine; Kermanshah University of Medical Sciences, Kermanshah, Iran
Abolfazl Movafagh
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Corresponding Author(s) : Abolfazl Movafagh

movafagh_a@yahoo.com

Cellular and Molecular Biology, Vol. 64 No. 9: Issue 9

Abstract

Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder characterized by the genetic translocation t(9;22) (q34;q11.2) encoding for the BCR-ABL fusion oncogene. Growing body of evidence suggests that epigenetic abnormalities are involved in tyrosine kinase resistance in CML, leading to leukemic clone escape and disease propagation. The significant of therapeutic role in chronic myeloid leukemia (CML) depends on both genetic and epigenetic mechanisms.  This article focused on the CML and epigenetic and clinical significance. An electronic search of peer-reviewed articles was systematically performed to obtain the relevant literature with the CINAHL, cancer, Google scholar, self-experience and PubMed databases. The keywords included leukemia, cancer, illness, epigenetic. The inclusion criteria for the reviews were that the documents were original quantitative research and published in English. Articles that were not directly relevant to the present objective were excluded. Current progress in molecular biology and bioinformatics offer novel promising experiments namely as next generation sequencing for new development in epigenetic figures characterization and more understanding of the epigenetic mechanisms to be successfully utilized for personalized CML therapy in the next coming years.

Keywords

Epigenetics CML Cancer Mechanisms MiRNAs.
Keramatinia, A., Ahadi, A., Akbari, M. E., Mohseny, M., Mosavi Jarahi, A., Bahadori-Monfared, A., Hashemi, M., Moradi, A., Mehrvar, N., Kazemi, E., & Movafagh, A. (2018). The roles of DNA epigenetics and clinical significance in Chronic Myeloid Leukemia: a review. Cellular and Molecular Biology, 64(9), 58–63. https://doi.org/10.14715/cmb/2018.64.9.9
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014 Jul 24;124(4):546-54. doi: 10.1182/blood-2014-03-559690.
  2. Puente XS, Beí S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015 Oct 22;526(7574):519-24. doi: 10.1038/nature14666.
  3. Moussay E, Palissot V, Vallar L, Poirel HA, Wenner T, El Khoury V, et al. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer. 2010 May 20;9:115. doi: 10.1186/1476-4598-9-115.
  4. Zhou K, Yu Z, Yi S, Li Z, An G, Zou D, et al. miR-29c down-regulation is associated with disease aggressiveness and poor survival in Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Jul;55(7):1544-50. doi: 10.3109/10428194.2013.855308.
  5. Rodrí­guez-Vicente AE, Quwaider D, Benito R, Misiewicz-Krzeminska I, Hernández-Sánchez M, et al. MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. BMC Cancer. 2015 Apr 8;15:238. doi: 10.1186/s12885-015-1212-2.
  6. Hansen TB, Kjems J, Bramsen JB. Enhnacing miRNA annotation confidence in miRBase by continuous cross dataset analysis. RNA Biol. 2011;8:378–83.
  7. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Jose-Eneriz ES, et al. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res. 2007 Nov;31(11):1521-8.
  8. Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica. 2010 Aug;95(8):1325-33. doi:
  9. 3324/haematol.2009.020636.
  10. Machová Poláková K, Lopotová T, Klamová H, et al. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer. 2011;10:41.
  11. Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007 May 15;109(10):4399-405.
  12. Scholl V, Hassan R, Zalcberg IR. miRNA-451: A putative predictor marker of Imatinib therapy response in chronic myeloid leukemia. Leuk Res. 2012 Jan;36(1):119-21. doi: 10.1016/j.leukres.2011.08.023.
  13. Suresh S, McCallum L, Lu W, Lazar N, Perbal B, Irvine AE. MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML. J Cell Commun Signal. 2011 Aug;5(3):183-91. doi: 10.1007/s12079-011-0139-x.
  14. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993 Oct 8;75(1):175-85.
  15. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem. 1994 Sep 16;269(37):22925-8.
  16. Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Grazia Borrello M, et al. Constitutive phosphorylation of Shc proteins in human tumors. Oncogene. 1995 Sep 7;11(5):899-907.
  17. Cahill MA, Janknecht R, Nordheim A. Signalling pathways: jack of all cascades. Curr Biol. 1996 Jan 1;6(1):16-9.
  18. Khazaei Koohpar Z, Entezari M, Movafagh A, Hashemi M. Anticancer Activity of Curcumin on Human Breast Adenocarcinoma: Role of Mcl-1 Gene. Iran J Cancer Prev. 2015 May;8(3):e2331. doi: 10.17795/ijcp2331.
  19. Heidari MH, Porghasem M, Mirzaei N, Mohseni JH, Heidari M, Azargashb E, et al. The effect of high level natural ionizing radiation on expression of PSA, CA19-9 and CEA tumor markers in blood serum of inhabitants of Ramsar, Iran. J Environ Radioact. 2014 Feb;128:64-7. doi: 10.1016/j.jenvrad.2013.11.001.
  20. Li Y, Yuan Y, Tao K, Wang X, Xiao Q, Huang Z, et al. Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate. PLoS One. 2013 Apr 16;8(4):e61858. doi: 10.1371/journal.pone.0061858.
  21. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science. 2004 Apr 23;304(5670):594-6.
  22. Chen C, Zhang Y, Zhang L, Weakley SM, Yao Q. MicroRNA-196: critical roles and clinical applications in development and cancer. J Cell Mol Med. 2011 Jan;15(1):14-23. doi: 10.1111/j.1582-4934.2010.01219.x.
  23. Liu Y, Song Y, Ma W, Zheng W, Yin H. Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia. Leuk Res. 2013 Mar;37(3):349-56. doi: 10.1016/j.leukres.2012.12.003.
  24. Patnaik SK, Kannisto E, Mallick R, Yendamuri S. Overexpression of the lung cancer-prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells. PLoS One. 2011;6(7):e22379. doi: 10.1371/journal.pone.0022379.
  25. Víµsa U, Vooder T, Kolde R, Fischer K, Välk K, Tíµnisson N, et al. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer. Genes Chromosomes Cancer. 2011 Oct;50(10):812-22. doi:
  26. Torii S, Yamamoto T, Tsuchiya Y, Nishida E. ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci. 2006 Aug;97(8):697-702.
  27. Li Y, Wang H, Tao K, Xiao Q, Huang Z, Zhong L, et al. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein. Exp Cell Res. 2013; 319:1094-1101.
  28. Polakova KM, Lopotová T, Klamová H, Burda P, Trnć›ní½ M, Stopka T, et al. Expression patterns of microRNAs associated with CML phases and their disease related targets. Molecular cancer. 2011; 10:41-53.
  29. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Current Biology. 2002; 12:735-739.
  30. Obernosterer G, Leuschner PJ, Alenius M, Martinez J. Post-transcriptional regulation of microRNA expression. RNA. 2006; 12:1161-1167.
  31. Liu X, Jiang L, Wang A, Yu J, Shi F, Zhou X. MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer letters. 2009; 286:217-222.
  32. Xu C, Fu H, Gao L, Wang L, Wang W, Li J, Li Y, et al. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia. Oncogene. 2014; 33:44-54.
  33. Prosser S, Sorokina E, Pratt P, Sorokin A. CrkIII: a novel and biologically distinct member of the Crk family of adaptor proteins. Oncogene. 2003; 22:4799-4806.
  35. Matsuda M, Tanaka S, Nagata S, Kojima A, Kurata T, Shibuya M. Two species of human CRK cDNA encode proteins with distinct biological activities. Molecular and Cellular Biology. 1992; 12:3482-3489.
  36. Bell ES, Park M. Models of crk adaptor proteins in cancer. Genes Cancer. 2012; 3:341-52. doi: 10.1177/1947601912459951.
  37. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. Journal of Biological Chemistry. 1994; 269:22925-22928.
  38. Meister J, Schmidt MH. miR-126 and miR-126*: new players in cancer. Scientific World Journal. 2010; 10:2090-2100.
  39. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, et al. Targeted deletion reveals essential and overlapping functions of the miR- 17 through 92 family of miRNA clusters. Cell. 2008; 132:875-886.
  40. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008; 15:261-271.
  41. Zhang J, Han L, Ge Y, Zhou X, Zhang A, Zhang C, et al. miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. Int J Oncol. 2010 Apr;36(4):913-20.
  42. Machová Poláková K, Lopotová T, Klamová H, Burda P, Trnć›ní½ M, et al. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer. 2011 Apr 18;10:41. doi:
  43. 1186/1476-4598-10-41.
  44. Simon MA, Dodson GS, Rubin GM. An SH3-SH2-SH3 protein is required for p21Ras1 activation and binds to sevenless and Sos proteins in vitro. Cell. 1993 Apr 9;73(1):169-77.
  45. Rogge RD, Karlovich CA, Banerjee U. Genetic dissection of a neurodevelopmental pathway: Son of sevenless functions downstream of the sevenless and EGF receptor tyrosine kinases. Cell. 1991 Jan 11;64(1):39-48.
  46. Rokah OH, Granot G, Ovcharenko A, Modai S, Pasmanik-Chor M, Toren A, Shomron et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One. 2012;7(4):e35501. doi: 10.1371/journal.pone.0035501.
  47. Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007 Jul 1;67(13):6031-43.
  48. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009 Dec 15;23(24):2839-49. doi: 10.1101/gad.1861409.
  49. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013 Dec;20(12):1603-14. doi: 10.1038/cdd.2013.125.
  50. Movafagh A, Maleki F, Fadaie S, AzarGashb E. Persistent unstable chromosomal aberrations in lymphocytes of radiotherapy workers after 1st mitotic division in Tehran, Iran. Pakistan Journal of Medical Sciences. 2007; 23:254-258.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 1035 Download : 471

Most read articles by the same author(s)

<< < 1 2